Oculis Holding Ag - (OCS) closed at $7.90 on October 23, 2026, down 2.3% from the previous close, on volume of 282,644 shares (30-day average 300,524).
Data as of October 23, 2026.
Globe Newswire (Thu, 22-Oct 2:00 AM ET)
Market Chameleon (Tue, 20-Oct 7:50 AM ET)
Globe Newswire (Tue, 20-Oct 2:00 AM ET)
Globe Newswire (Mon, 19-Oct 2:00 AM ET)
Globe Newswire (Wed, 7-Oct 1:59 AM ET)
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
Globe Newswire (Thu, 1-Oct 2:00 AM ET)
Oculis Announces Resignation of Lionel Carnot from Board of Directors
Globe Newswire (Wed, 30-Sep 5:31 PM ET)
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Globe Newswire (Mon, 24-Aug 4:00 AM ET)
Globe Newswire (Mon, 10-Aug 3:30 AM ET)
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.
As of October 26, 2026, OCS stock price declined to $7.84 with 37,566 million shares trading.
OCS has a beta of 2.71, meaning it tends to be more sensitive to market movements. OCS has a correlation of 0.13 to the broad based SPY ETF.
OCS has a market cap of $453.21 million. This is considered a Small Cap stock.
Last quarter Oculis Holding Ag - reported $392,150 in Revenue and -$.20 earnings per share. This beat revenue expectation by $132,150 and exceeded earnings estimates by $.28.
In the last 3 years, OCS traded as high as $34.48 and as low as $7.11.
The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, BBC, GWX, ONEQ.
OCS has underperformed the market in the last year with a price return of -63.3% while the SPY ETF gained +15.3%. OCS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.5% and -6.0%, respectively, while the SPY returned +4.2% and -1.5%, respectively.
OCS support price is $7.61 and resistance is $8.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.
